A spokesman for Daiichi Sankyo indicated that the daily listed cost of Lixiana is £2.10, although he told pharmaphorum that "costs around the country may vary because of negotiated procurement ...

Daiichi Sankyo has more than 120 years of experience and scientific expertise. In 2019, they entered the oncology market in the UK, through a ground-breaking collaboration with AstraZeneca.

Pharma AZ, Daiichi's Datroway scores its 2nd FDA approval—this time in lung cancer subset By Kevin Dunleavy Jun 24, 2025 8:10am Datroway Daiichi Sankyo AstraZeneca antibody-drug conjugates ...

Following approval in the US, AstraZeneca is required to pay $45 million to Daiichi Sankyo as a milestone payment for the locally advanced or metastatic EGFR-mutated NSCLC indication.

AstraZeneca & Daiichi Sankyo’s Datroway gets US approval for patients with previously treated advanced EGFR-mutated NSCLC Cambridge, UK Wednesday, June 25, 2025, 09:00 Hrs [IST] Datroway (datopotamab ...

Datroway has been approved in the United States, the world's biggest pharmaceuticals market, to treat an advanced form of non-small cell lung cancer in adults who had received prior treatment, ...

Backed by Perceptive Xontogeny Venture Funds and venBio Partners, the new biotech will make genetic medicines that don’t rely ...

Speakers' Bureau: Roche/Genentech, Novartis, Pfizer, Lilly, Foundation Medicine, Samsung, Daiichi Sankyo, Seagen, Menarini, Gilead Sciences, AstraZeneca, Exact Sciences Research Funding: Merck (Inst) ...

Daiichi Sankyo and MSD's partnership, which began in October 2023, encompasses the co-development and commercialisation of patritumab deruxtecan (HER3-DXd), raludotatug deruxtecan (R-DXd), and I-DXd.

View the latest Daiichi Sankyo Co. Ltd. (DSKYF) stock price, news, historical charts, analyst ratings and financial information from WSJ.